Roche Licenses Chiasma’s Late-Stage Oral Acromegaly Therapy
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 2 (Table of Contents)
Published: 26 Feb-2013
DOI: 10.3833/pdr.v2013.i2.1902 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Roche has added a Phase III asset to its development pipeline by licensing global development and commercialisation rights to Israeli biotech Chiasma’s lead drug candidate Octreolin®, an oral form of the somatostatin analogue octreotide that is commercially available only by painful injection...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS